Stocktoria
LeonaBio, Inc. LONA
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2020-09-18
LeonaBio, Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| R&D expense | $17.5M | $70.7M | $93.8M | $61.5M | $42.8M |
| Operating income | -$102.3M | -$100.9M | -$125.5M | -$104.0M | -$64.0M |
| Interest expense | — | — | — | — | $3,000 |
| Income tax | $0 | — | — | — | — |
| Net income | -$105.6M | -$96.9M | -$117.7M | -$95.6M | -$54.9M |
| EPS (diluted) | $-24.70 | $-25.19 | $-3.09 | $-2.53 | $-1.49 |
| Operating cash flow | -$45.7M | -$97.2M | -$100.8M | -$72.5M | -$43.1M |
| Free cash flow | — | -$97.2M | -$101.1M | -$73.6M | -$44.7M |
| Cash & equivalents | $69.3M | $48.4M | $90.6M | $96.0M | $110.5M |
| Total assets | $92.2M | $58.8M | $160.2M | $258.2M | $332.0M |
| Total liabilities | $64.4M | $13.9M | $30.1M | $23.0M | $10.9M |
| Shareholders' equity | $27.8M | $44.8M | $130.2M | $235.1M | $321.1M |
Source: SEC EDGAR filings · CIK 0001620463 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.